About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
CYTK - Cytokinetics| Previous Close | $19.68 | Open | $19.76 |
| Volume | 1.15M | Market Cap | 1.321B |
| Yield | Last Dividend |
| Cytokinetics to Present at the H.C. Wain... | 01/06/21 |
| SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, Presiden... | |
| Morgan Stanley Stick to Their Buy Rating... | 12/16/20 |
| Morgan Stanley Stick to Their Buy Rating for Cytokinetics | |
| Mizuho Securities Stick to Their Buy Rat... | 12/14/20 |
| Mizuho Securities Stick to Their Buy Rating for Cytokinetics | |
| Bvf Partners L. P/Il Sells 430,954 Share... | 12/13/20 |
| Cytokinetics, Incorporated (NASDAQ:CYTK) insider Bvf Partners L. P/Il sold 430,954 shares of Cytokinetics stock in a transaction on Wednesday, Decembe... | |
| Needham Stick to Their Buy Rating for Cy... | 12/09/20 |
| Needham Stick to Their Buy Rating for Cytokinetics | |
| H.C. Wainwright Stick to Their Buy Ratin... | 12/07/20 |
| H.C. Wainwright Stick to Their Buy Rating for Cytokinetics | |
| Insider Selling: Cytokinetics, Incorpora... | 12/07/20 |
| Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum sold 5,000 shares of the firm???s stock in a transaction dated Friday, December 4th. The s... | |
| Amgen severs 14-year Cytokinetics partne... | 11/23/20 |
| Amgen is shrugging off a 14-year development alliance and the tens of millions of dollars spent to develop a new heart drug at Cytokinetics after a Ph... | |
| CYTOKINETICS INC : Termination of a Mate... | 11/23/20 |
| Item 1.02. Termination of a Material Definitive Agreement. On November 20, 2020, Cytokinetics, Incorporated received written notice of termination fro... | |
| Cytokinetics Names Nancy Wysenski to Boa... | 11/20/20 |
| Appointment Strengthens Commercial, Market Access and Specialty Sales Expertise as Company Advances Pipeline Toward Potential Commercialization | |
| Cytokinetics Heart Failure Drug Succeeds... | 11/13/20 |
| Cytokinetics Inc on Friday said a pivotal trial of the experimental heart failure drug it is developing with Amgen Inc showed a slightly higher rate o... | |
| STAT+: Concerns linger over Cytokinetics... | 11/13/20 |
| Cytokinetics and Amgen presented updated data on a novel drug designed to increase the tension within the muscles of the heart, thereby improving its ... | |
| Cytokinetics Announces Six Presentations... | 11/06/20 |
| Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session Cytokinetics to Host Investor/Media Event and Webcast Related... | |
| Analysts??? Recent Ratings Changes for C... | 10/21/20 |
| Cytokinetics (NASDAQ: CYTK) has recently received a number of price target changes and ratings updates: 10/17/2020 ??? Cytokinetics was downgraded by ... | |
| Cytokinetics, Inc. (NASDAQ:CYTK) Expecte... | 10/21/20 |
| Equities analysts expect Cytokinetics, Inc. (NASDAQ:CYTK) to report earnings of ($0.59) per share for the current fiscal quarter, Zacks Investment Res... | |
| Cytokinetics, Inc. (NASDAQ:CYTK) Expecte... | 10/21/20 |
| Wall Street analysts expect Cytokinetics, Inc. (NASDAQ:CYTK) to report $3.80 million in sales for the current quarter, Zacks reports. Two analysts hav... | |
| BidaskClub Downgrades Cytokinetics (NASD... | 10/20/20 |
| BidaskClub lowered shares of Cytokinetics (NASDAQ:CYTK) from a buy rating to a hold rating in a research report released on Saturday morning, BidAskCl... | |
| Bulbospinal Muscular Atrophy Drugs Marke... | 10/19/20 |
| Global Bulbospinal Muscular Atrophy Drugs Market is growing at a steady CAGR in the forecast period of 2019-2026. The report contains data of the base... | |
| Coty, Eaton Vance rise; Domino's, Cytoki... | 10/08/20 |
| Stocks that moved heavily or traded substantially Thursday: Coty, Eaton Vance rise; Domino???s, Cytokinetics fall | |
| FXNEWS24 |BUZZ-U.S. STOCKS ON THE MOVE-M... | 10/08/20 |
| BUZZ-U.S. STOCKS ON THE MOVE-Medtronic, Carnival, JetBlue Airways, Bausch Well being, Gilead, Cytokinetics | UK Stocks, Forex, Commodities, Crypto, Li... | |
| Why Cytokinetics Is Trading Lower Today | 10/08/20 |
| Cytokinetics (NASDAQ: CYTK ) shares are trading lower on Thursday after the company, Amgen and Servier announced topline results from GALACTIC-HF, a P... | |
| STAT Plus: Study of experimental heart d... | 10/08/20 |
| Cytokinetics and Amgen said their study of an experimental heart drug achieved its main goal, but the treatment effect was marginal. | |
| Cytokinetics Incorporated : Corporate Pr... | 08/18/20 |
| 35/94 ??? | August 18, 2020 | |
| Cytokinetics Reports Second Quarter 2020... | 08/06/20 |
| Top-line Results from GALACTIC-HF Expected in Q4 2020 Licensing Collaboration, Royalty Monetizations and Financing Provide Additional Capitalto Suppor... | |
| Cytokinetics Incorporated : Corporate Pr... | 07/21/20 |
| 35/94 ??? | July 22, 2020 | |
| Cytokinetics Announces Closing of Public... | 07/21/20 |
| SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the closing of its previously?... | |
| Cytokinetics readies $150M stock offerin... | 07/15/20 |
| Cytokinetics (NASDAQ:CYTK) initiates a $150M public offering of common stock. Price, volume and terms have yet to be announced. | |
| Cytokinetics inks deal for CK-3773274 wi... | 07/14/20 |
| Cytokinetics (NASDAQ:CYTK) has agreed to a series of transactions with certain companies wholly owned by investment funds managed by RTW Investments, ... | |
| Cytokinetics Announces Licensing Collabo... | 07/14/20 |
| $250 Million in Committed Capital to Cytokinetics;Additional $200 Million in Development and Commercialization Milestone Payments Ji Xing Pharmaceutic... | |
| Cytokinetics Announces Licensing Collabo... | 07/14/20 |
| $250 Million in Committed Capital to Cytokinetics;Additional $200 Million in Development and Commercialization Milestone Payments Ji Xing??? | |
| Buy rating | 01/20/21 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $22.00 to $41.00 | |
| Strong Buy rating | 12/16/20 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $22.00 to $24.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| FEAT. ANDRE 3000 | JOHN KROLIKOWSKI JR | 91.00 % | Subscribe |
| Tech Trades | Tech Trades | 82.00 % | Follow |
| WIDE AWAKE | JOHN KROLIKOWSKI JR | 81.00 % | Follow |
| Arbitrage Trade Analytics | Royce Wells | 72.00 % | Subscribe |
| OG | AL GORE RHYTHMS | 40.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
